New RA drug JADE201 enters first human safety trial
NCT ID NCT07533955
First seen Apr 22, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug, JADE201, in 36 adults with rheumatoid arthritis. The main goal is to see if single doses are safe and how the body processes the drug. Participants will receive either JADE201 or a placebo by injection, and researchers will monitor side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jade Clinical Site
Chisinau, Moldova, 2025, Moldova
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jade Clinical Site
Ivano-Frankivsk, Ukraine, 76018, Ukraine
-
Jade Clinical Site
Kyiv, Ukraine, 02000, Ukraine
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.